Claims:

1. A pharmaceutical composition comprising a slow release tapentadol and at least one pharmaceutically acceptable carrier, and a second active agent, wherein the second active agent is pregabalin, or pharmaceutically acceptable salts thereof.

2. The pharmaceutical composition of claim 1, wherein the tapentadol is tapentadol hydrochloride.

3. The pharmaceutical composition of claim 1 or 2, wherein the pregabalin is present in an immediate release form, extended (controlled) release form or delayed release form along with a pharmaceutically acceptable carrier.

4. The pharmaceutical composition of any of claims 1-3, comprising an immediate release coating wherein the immediate release coating comprises the pregabalin.

5. The pharmaceutical composition of any of claims 1-3, wherein the composition is a bilayer composition comprising a slow-release tapentadol layer, and a layer comprising the pregabalin.

6. The pharmaceutical composition of any of claims 1-5, wherein the composition exhibits an in vitro dissolution profile such that after 2 hours, from about 0% to about 30% by weight of tapentadol is released, after 4 hours, from about 5% to about 22% by weight of tapentadol is released, after 6 hours, from about 15% to about 30% by weight of tapentadol is released, and after 8 hours more than about 40% by weight of tapentadol is released; when measured using USP Basket Method at 75 rpm in 900 ml 0.1 N HCl at 37 °C.

7. The pharmaceutical composition of any of claims 1-6, wherein the composition is a coated tablet wherein the coating comprises at least one water-insoluble, water permeable film-forming polymer, at least one plasticizer and at least one water-soluble polymer, and the second active agent.

8. The pharmaceutical composition of any of claims 1-7, wherein the proportion of the water-insoluble, water-permeable film-forming polymer is about 20% to about 90% of the coating dry weight, the proportion of the plasticizer is about 5% to about 30% of the coating dry weight, and the proportion of the water-soluble polymer is about 10% to about 75% of the coat dry weight.

9. The pharmaceutical composition of claim 8, wherein the water-insoluble, water-permeable film- forming polymer is ethylcellulose, the water-soluble polymer is polyvinylpyrrolidone and the plasticizer is dibutyl sebacate and/or wherein the core comprises a lubricant, a binder, a glidant, or any combination thereof and/or wherein the carrier comprises an adjuvant, a preservative, an antioxidant, a thickening agent, a chelating agent, an antifungal agent, an antibacterial agent, an isotonic agent, a flavoring agent, a sweetening agent, an anti-foaming agent, a colorant, a diluent, a moistening agent, a parietal cell activator, or a combination thereof.

10. The pharmaceutical composition of any of claims 1-9, wherein the tapentadol is present in an amount of from about 5 mg to about 400 mg.

11. The pharmaceutical composition of any of claims 1-10, wherein the pregabalin is present in an amount of from about 5 mg to about 500 mg.

12. Pharmaceutical composition of any of claims 1-11 for use in treating pain.

13. Pharmaceutical composition of claim 12 for use in treating neuropathic pain, osteoarthritis, rheumatoid arthritis, fibromyalgia, and back, musculoskeletal pain, ankylosing spondylitis, juvenile rheumatoid arthritis, diabetic neuropathy, migraines, dental pain, abdominal pains, ischemic pain, postoperative pain or because of an anesthetic or surgical contrition.